Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Our overall aim is to characterise new drug scaffolds and their novel binding sites on HIV reverse transcriptase to advance fundamental understanding of reverse transcriptase structure and function and to underpin the discovery of a new HIV drug class.
This new drug class is aimed to have a distinct mechanism of action and resistance profile to drugs currently used for HIV treatment and prevention
2017 – 2019
Associate Professor David Chalmers Professor Nicolas Sluis-Cremer Professor Eddy Arnold Associate Professor Philip Thompson Dr Stephen Headey Dr Catherine Latham Dr Joseph Bauman Professor Martin Scanlon Professor Susan Charman
NHMRC
For any general enquiries relating to this project, please contact:
Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
